Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

This Journal of Clinical Investigation review describes how glucagon-like peptide-1 (GLP-1)–based medicines reduce systemic and tissue inflammation through both weight-dependent and weight-independent ...

During National Diabetes Month, we recognize the millions of Americans living with diabetes and we renew our commitment to building a healthier Nation.

The CMS has finalized the first cycle of drug price negotiations under the IRA, establishing precedent for improved ...

People with type 2 diabetes who took low-dose aspirin were less likely to have a heart attack or stroke, University of Pittsburgh researchers reported.

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...

Type 1 diabetes is an autoimmune disease (typically arising in younger people) that occurs when your immune system attacks ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Groundbreaking diabetes and weight loss drugs like Ozempic and Mounjaro are transforming treatment, offering significant weight loss. However, access ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...